ProCE Banner Activity

CheckMate 511: 3-Year Follow-up of 2 Different Dosing Regimens of Nivolumab + Ipilimumab for Patients With Advanced Melanoma

Slideset Download
Conference Coverage
Three-year follow-up of CheckMate 511 shows continued improved safety and comparable efficacy of NIVO3 + IPI1 vs NIVO1 + IPI3 for patients with advanced melanoma.

Released: June 06, 2021

Expiration: June 05, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme